What were the key takeaways from Liquidia’s earnings call?

What guidance did Liquidia's management provide for the next earnings period?

What is Liquidia's latest dividend and current dividend yield?

What were the key takeaways from Liquidia's earnings call?

What is the market's earnings forecast for Liquidia next quarter?

What is the revenue and EPS growth rate for Liquidia year over year?

What factors drove the changes in Liquidia's revenue and profit?

What does Liquidia do and what are its main business segments?

- **Revenue Growth**: $148.3M in 2025 net product sales, up 74% YoY in Q4. 
- **Patient Momentum**: 2,900+ patients shipped, 85%+ conversion rate, 860 prescribers. 
- **Market Leadership**: 17% Q4 2025 inhaled treprostinil share, outpacing competitor SMI. 
- **Financial Strength**: $190.7M cash, $33M Q4 cash flow, $14.6M net income. 
- **Pipeline Ambition**: L-606 study launch, $1B+ 2027 target, expanding into PH-COPD and systemic sclerosis.

**【CEO Summary Section】**
- YUTREPIA achieved 3,600 unique patient referrals and 2,900 shipped therapies by Q1 2026, maintaining strong growth despite seasonal concerns. Market share is rising, with equal splits between PAH and PH-ILD. 
- Q4 2025 net product sales reached $90.1 million, up 74% YoY, driven by 80% QoQ revenue growth. 
- L-606 pivotal study to begin in 2026, targeting expanded disease areas like systemic sclerosis-associated Raynaud’s and PH-COPD. 
- 2027 goal: $1 billion+ revenue, with $148.3 million in 2025 net product sales and $33 million positive cash flow.

**【CFO Financial Commentary】**
- Full year 2025 net product sales: $148.3 million (Q4: $90.1 million). 
- Q4 2025 non-GAAP adjusted EBITDA: $27.3 million; net income: $14.6 million. 
- Cash position: $190.7 million as of Q4 2025, with $33 million Q4 cash flow. 
- 85%+ prescription-to-patient start conversion rate maintained, despite 25% of patients switching from competitors.

**【Q&A Key Highlights】**
- **Market Share & Competition**: 17% Q4 2025 inhaled treprostinil revenue share vs. 10% Q3. SMI competitor’s product seen as “more of the same” with GI side effects, no impact on YUTREPIA trajectory. 
- **Patient Growth**: 75% naive starts vs. 25% switches; 860 prescribers, 25% with >5 referrals. 
- **Payer Access**: 85%+ pull-through rate; expanding sales force by 33% to target PH-ILD. 
- **Future Trials**: Switch studies from oral to YUTREPIA, sotatercept combination, and parenteral transitions. L-606 to reduce dosing frequency to twice daily.

Liquidia Technologies Inc (LQDA) Q4 2025 Earnings Call Transcript

- **Commercial Success**: YUTREPIA achieved 2,000+ prescriptions and 1,500+ patient starts with 85% pull-through rate, outperforming Tyvaso's growth. 
- **Financial Discipline**: $51.7M in sales with positive EBITDA and first positive cash flow month, balancing R&D investment. 
- **Litigation Risk**: Ongoing patent case with potential market exclusion or royalty risks. 
- **Strategic Expansion**: Planning trials in IPF/PPF and advancing L606 for 2026 growth.

**【CEO Summary Section】**
- YUTREPIA achieved 2,000+ unique prescriptions and 1,500+ patient starts. The 85% referral-to-start ratio, with 75% naive patients and 25% transitions from inhaled therapies. Clinical expansion plans include trials for PAH transitioning from oral prostacyclins and exploratory studies in IPF/PPF. The company aims to maintain profitability while investing in R&D, with L606's pivotal RESPIRE study launching in H2 2025.

**【CFO Financial Commentary】**
- Q3 2025 net product sales of $51.7M, with $3.6M net loss but $10.1M non-GAAP adjusted EBITDA. September marked the first month of positive net cash flow ($5M), driven by disciplined cash management. The company expects sustained growth in 2026, balancing reinvestment in R&D with profitability.

**【Q&A Highlights】**
- **Market Access Strength**: 85% pull-through rate, contracts with top 3 commercial payers, and removal of new-to-market blocks. **Litigation Risk**: Ongoing patent infringement case with United Therapeutics, with uncertain remedies (royalty or market exclusion). **Patient Engagement**: 50% voucher usage for 28-day trials, supporting early adoption. **Competitive Dynamics**: YUTREPIA captured 75% of market growth vs. Tyvaso's $14.8M increase, driven by product differentiation.

Liquidia Corporation (LQDA) Q3 2025 Earnings Call Transcript

- **Breakout Launch**: YUTREPIA achieved 550 patient starts in 11 weeks, with 75% script-to-start conversion and unprecedented tolerability (18.5% cough-related discontinuations).
- **Financial Strength**: $173M cash balance supports expansion, with Q2 revenue of $8.8M driven by YUTREPIA sales.
- **Growth Drivers**: Accelerating weekly prescriptions, expanding payer access, and a pipeline refresh with L606 data in Q4.
- **Competitive Edge**: Flexible dosing (up to 318mcg) and ease of use are outperforming TYVASO DPI, driving unexpected switch volume.

**【CEO Summary Section】**
- YUTREPIA achieved a record launch with 900+ unique patient prescriptions and 550 starts within 11 weeks, surpassing expectations in the prostacyclin market.
- The product's differentiated profile, including ease of use, low cough incidence (only 18.5% discontinuations for cough), and flexible dosing, has driven a 75% script-to-start conversion rate.
- Clinical data from the ASCENT study shows median 6-minute walk improvements of 31.5 meters at week 16, with tolerability enabling dose escalation to 318 micrograms (equivalent to 36 TYVASO nebulizer breaths).
- Management highlights the potential for accelerating growth as new-to-market blocks are removed and payer access expands.

**【CFO Financial Commentary】**
- Q2 2025 revenue reached $8.8 million, with $6.5 million from YUTREPIA sales and $2.3 million from the Sandoz treprostinil agreement.
- Cash balance of $173 million supports commercial expansion, with plans to triple manufacturing capacity in 2026.
- R&D expenses are expected to increase for pivotal L606 studies, while SG&A costs (excluding sales variable costs) will remain stable.

**【Q&A Key Highlights】**
- **Growth Momentum**: Weekly prescription volume is accelerating, with early adopters driving word-of-mouth adoption among community physicians.
- **Patient Mix**: Over 75% of starts are new-to-prostacyclin, but unexpected switch volume from TYVASO DPI and oral prostacyclins is contributing to upside.
- **Payer Access**: Contracts with major commercial payers are in place, with new-to-market blocks expected to lift in Q3, enabling full rebate participation.
- **L606 Pipeline**: The company plans an R&D Day in Q4 to share 1-year data from the open-label L606 study, positioning it as a potential best-in-class ILD therapy.
- **Litigation Update**: The 327 patent trial concluded in June; a decision is expected within 2-3 months, with no material impact on YUTREPIA's exclusivity anticipated.

Liquidia Corporation (LQDA) Q2 2025 Earnings Call Transcript

- **Regulatory Win**: Court dismissal of United Therapeutics' challenge clears path for YUTREPIA approval
- **Clinical Momentum**: ASCENT trial shows 3x higher dosing in PH-ILD patients with positive efficacy trends
- **Financial Focus**: Q1 2025 net loss widens to $38.4M as company ramps up commercialization expenses
- **Launch Readiness**: 50+ sales reps, patient support services, and 2-3 week product availability post-approval

**【CEO Opening Remarks】**
- **YUTREPIA Regulatory Update**: District Court dismissed United Therapeutics' cross-claim, citing lack of standing. No legal barriers remain for potential approval on May 23, 2025.
- **Strategic Focus Areas**: 
  1. Best-in-class product profile with tolerability and ease of use
  2. Market readiness with 50+ sales reps and medical affairs team
  3. Patient support services and product availability
  4. Payer access through established relationships
- **Clinical Trial Progress**: 
  - ASCENT Cohort A (50+ PH-ILD patients) shows 3x higher dosing than TYVASO with positive 6-minute walk trends
  - Cohort B to begin transitioning patients from TYVASO

**【CFO Financial Overview】**
- **Q1 2025 Financials**: 
  - Revenue: $3.1M (flat YoY) from promotion agreement
  - R&D Expenses: $7M (-31% YoY) due to shift to commercialization
  - G&A Expenses: $30.1M (+48% YoY) driven by headcount and legal fees
  - Net Loss: $38.4M (-27% YoY) due to higher expenses
- **Key Drivers**: 
  - Personnel costs up 48% for commercial prep
  - Legal fees increased by $0.6M

**【CEO Closing Remarks】**
- Reiterates confidence in YUTREPIA's potential as 'prostacyclin of first choice'
- Highlights comprehensive launch readiness across clinical, commercial, and patient support dimensions

Liquidia (LQDA)-8 May 25-2025 Q1 Earnings call transcript

- **YUTREPIA Launch Imminent**: Final FDA approval expected May 23, 2025; ASCENT trial shows 3x higher doses vs. TYVASO with superior efficacy. 
- **Financial Strength**: $100M capital raise provides runway to profitability; 2024 net loss driven by R&D and commercial buildout. 
- **Pipeline Momentum**: L606 Phase III to start Q4; sustained-release formulation addresses systemic side effects. 
- **Market Opportunity**: PH-ILD market expansion with 50% Medicare coverage; YUTREPIA's dose-titration profile positions as best-in-class.

**【CEO Strategic Overview】**
- **YUTREPIA Launch Timeline**: Plans to submit for final FDA approval by mid-March 2025, targeting May 23, 2025, when competitor exclusivity expires. 
- **Clinical Differentiation**: ASCENT trial shows PH-ILD patients on YUTREPIA achieved 3x higher doses than TYVASO DPI, with 26.4m mean improvement in 6-minute walk test vs. 16m in TYVASO's INCREASE study. 
- **Commercial Readiness**: 14-month seasoned sales team of rare disease experts; expects seamless launch with existing supply chain. 
- **Pipeline Expansion**: L606 Phase III (INSPIRE) trial initiation by end-2025; sustained-release formulation aims to reduce systemic side effects. 

**【CFO Financial Update】**
- **2024 Financials**: Revenue $14M (down 21% YoY due to pump shortages), R&D $47.8M (up 11%), G&A $81.6M (up 82%), net loss $130.4M. 
- **Capital Raise**: Secured $100M from HealthCare Royalty (including $25M upfront), with potential for profitability post-YUTREPIA launch. 
- **Cash Runway**: $25M at closing, $50M on first sale, $25M at $100M sales; confident in achieving profitability without further dilution. 

**【Q&A Key Takeaways】**
- **Approval Process**: Class 1 resubmission expected to take ~60 days post-May 23; no new data required. 
- **L606 Feedback**: Physicians highlight twice-daily dosing convenience and reduced systemic toxicity; Phase III to start Q4 2025. 
- **Market Penetration**: Focus on PH-ILD underserved patients; Medicare ~50%, commercial 30-40%. 
- **Pricing Strategy**: Will balance patient access with YUTREPIA's superior dose-titration profile. 
- **ASCENT Data**: Dose escalation driven by PRINT technology's lower airway targeting; planning head-to-head trial vs. TYVASO DPI.

Actual							-0.52	-0.49	-0.35	-0.21	-0.13	-0.14	-0.22	-0.3	-0.15	-0.14	-0.08	-0.18	-0.36	-0.24	-0.43	-0.54	-0.37	-0.3	-0.45	-0.45	-0.49	-0.04	0.15
Forecast							-0.555	-0.445	-0.375	-0.2125	-0.1575	-0.12	-0.1225	-0.2075	-0.2374	-0.1754	-0.1561	-0.1629	-0.1624	-0.2151	-0.2367	-0.3235	-0.3415	-0.3737	-0.3749	-0.4049	-0.4315	-0.3893	0.2356
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+6.31%	-10.11%	+6.67%	+1.18%	+17.46%	-16.67%	-79.59%	-44.58%	+36.82%	+20.18%	+48.75%	-10.50%	-121.67%	-11.58%	-81.66%	-66.92%	-8.35%	+19.72%	-20.03%	-11.14%	-13.56%	+89.73%	-36.33%

LQDA

LQDA fundamentals

LQDA Q4 2025 Earnings

Earnings Call

You can ask Aime

LQDA

LQDA fundamentals

LQDA Q4 2025 Earnings

Earnings Call

LQDA Earnings Call Summary for Q4/20258:30 AM on Mar 5, 2026

LQDA Earnings Call Summary for Q3/20258:30 AM on Nov 3, 2025

LQDA Earnings Call Summary for Q2/20258:30 AM on Aug 12, 2025

LQDA Earnings Call Summary for Q1/20258:30 AM on May 8, 2025

LQDA Earnings Call Summary for Q4/20248:30 AM on Mar 19, 2025

You can ask Aime